CELC (Celcuity Corp) Forward P/E Multiple

Celcuity Therapeutics - graphic logo of issuer CELC

Celcuity Inc. is mitigating strategic risks by combining cellular diagnostics with the development of targeted therapies. The company's forward P/E on the GURU.Markets system chart shows a value of 0.00, which helps assess the probability of a business acquisition. Gedatolisib trials and FDA approvals are driving the growth in share prices. Simultaneously, the company is implementing robotic platforms to automate the analysis of oncology samples.

Price to Future Earnings Ratio: celcuity.com (CELC) for 07/04/2022 - 11/12/2026

Analytical breakdowns for Celcuity Therapeutics (CELC)

- current price and projected stock value:
Stock Quotes Celcuity|CELC - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Celcuity Inc|CELC - Enterprise Value
- book capitalization information:
Net Assets per Single Share Celcuity|CELC - Accounting Capitalization|Market Capitalization to Book Value Ratio celcuity.com|CELC - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Celcuity Inc.|CELC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Celcuity Inc.|CELC - Company Cumulative Debt|Debt to Book Capitalization Ratio Celcuity Inc|CELC - Long-Term Debt Volume|Company Short-Term Debts Celcuity|Quick Liquidity celcuity.com
- company profitability and valuation multiples indicators:
CELC - Net Financial Result|Projected Future Earnings Celcuity Inc.|CELC - Price to Earnings Ratio|Forward P/E Multiple Celcuity Corp|CELC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celcuity Inc|CELC - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Celcuity|CELC - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months celcuity.com|CELC - Earnings growth in current year|Earnings growth forecast for next year Celcuity Inc.
Analysis of all company metrics:CELC Celcuity
Signature product of celcuity.com

To assess long-term risks, an investor analyzes the forward P/E, which relates the market value of a share to expected net income to identify phases of asset overheating. The current forward P/E level of Celcuity Inc. (CELC) reflects market expectations for the monetization of the CELx platform, where the stability of the multiple confirms the value of deeply integrating diagnostic tests into the developments of major pharmaceutical partners.

Main competitors

Projected Price to Earnings CAI (Caris Life Sciences)|GH (Guardant Health Inc) - Future Price to Earnings Multiple|Forward P/E Multiple VCYT (Veracyte Corp)|Forward P/E Multiple GRAIL Bio GRAL|MYGN - Future Price to Earnings|CSTL (castlebiosciences.com) - Price to Future Earnings Ratio|BNR: Forward P/E Multiple|VolitionRx (VNRX) - Forward P/E Multiple|Future Price to Earnings Biodesix Corp|Future Price to Earnings PRPO|Projected Price to Earnings CHEK (Check-Cap Ltd.)|MYNZ - Projected Price to Earnings Ratio|Future Price to Earnings OncoCyte OCX